

Reference list of 191 Phase I articles

Paper "Put to the Test" by Lindy Bosch and Raymond Hoffmans

Published in European Biopharmaceutical Review, January 2015

- Agelaki, S. *et al.* A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. *Cancer chemotherapy and pharmacology* **72**, 45–51 (2013).
- Akiyama, Y. *et al.* α -type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. *BMC cancer* **12**, 623 (2012).
- Ando, M. *et al.* Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. *Cancer chemotherapy and pharmacology* **69**, 457–65 (2012).
- Annunziata, C. M. *et al.* Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. *Investigational new drugs* **31**, 77–84 (2013).
- Anthony, D. A. *et al.* Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. *BMC cancer* **12**, 536 (2012).
- Antonarakis, E. S. *et al.* Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. *Cancer chemotherapy and pharmacology* **69**, 763–71 (2012).
- Araki, K. *et al.* First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors. *Investigational new drugs* **30**, 2327–33 (2012).
- Arkenau, H.-T. *et al.* A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 1307–13 (2012).
- Aruga, A. *et al.* Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 2224–31 (2013).
- Asahina, H. *et al.* Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. *Investigational new drugs* **31**, 677–84 (2013).
- Asahina, H. *et al.* An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. *Cancer chemotherapy and pharmacology* **69**, 1477–86 (2012).
- Bagarazzi, M. L. *et al.* Immunotherapy Against HPV16 / 18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses. *Science translational medicine* **4**, 1–14 (2012).
- Baker, a F. *et al.* A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. *Investigational new drugs* **31**, 631–41 (2013).
- Baselga, J. *et al.* Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor , AEE788 Using Pharmacokinetic and Pharmacodynamic Data in Early. *Clin Cancer Res* **18**, 6364–6372 (2012).
- Beeram, M. *et al.* A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. *Cancer* **118**, 5733–40 (2012).
- Bendell, J. C. *et al.* Phase I , Dose-Escalation Study of BKM120 , an Oral Pan-Class I PI3K Inhibitor , in Patients With Advanced Solid Tumors. *Journal of Clinical Oncology* **30**, (2012).
- Bianchini, D. *et al.* First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. *British journal of cancer* **109**, 2579–86 (2013).
- Boss, D. S. *et al.* A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. *British journal of cancer* **106**, 1598–604 (2012).
- Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W.-J. & Topollian, S. L. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *The Journal of urology* **188**, 2148–2149 (2012).
- Burge, M. *et al.* Phase I, pharmacokinetic and Pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. *Investigational new drugs* **31**, 126–35 (2013).
- Burke, J. M. *et al.* A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. *The Journal of urology* **188**, 2391–7 (2012).
- Calvo, E. *et al.* Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. *Cancer chemotherapy and pharmacology* **69**, 1467–75 (2012).
- Capdevila, J. *et al.* A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 1247–54 (2013).
- Chao, J. *et al.* A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. *Cancer chemotherapy and pharmacology* **69**, 835–43 (2012).
- Cho, E.-A. *et al.* Safety and tolerability of an intratumorally injected DNzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). *Lancet* **381**, 1835–43 (2013).
- Chudley, L. *et al.* DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. *Cancer immunology, immunotherapy : CII* **61**, 2161–70 (2012).
- Chung, V. *et al.* First-time-in-human study of GSK923295, a novel antimetabolic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. *Cancer chemotherapy and pharmacology* **69**, 733–41 (2012).
- Cohen, R. B. *et al.* A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. *European journal of cancer (Oxford, England : 1990)* **49**, 1521–9 (2013).
- Cooney, M. M. *et al.* Phase I trial of pomalidomide given for patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 755–61 (2012).

- Crew, K. D. *et al.* Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. *Cancer prevention research (Philadelphia, Pa.)* **5**, 1144–54 (2012).
- Culine, S. *et al.* Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer. *Journal of geriatric oncology* **4**, 122–7 (2013).
- Dannull, J. *et al.* Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. *Clinical Medicine* **123**, 3135–3145 (2013).
- Daud, A. I., Krishnamurthi, S. S. & Saleh, M. N. Phase I Study of Bosutinib , a Src / Abl Tyrosine Kinase Inhibitor , Administered to Patients with Advanced Solid Tumors. *Clin Cancer Res* **18**, 1092–1100 (2012).
- Deeken, J. F. *et al.* A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. *Cancer chemotherapy and pharmacology* **71**, 627–33 (2013).
- Dees, E. C. *et al.* Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 4775–84 (2012).
- Delord, J. P. *et al.* Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. *Investigational new drugs* **31**, 724–33 (2013).
- Delord, J. P. *et al.* Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours. *Cancer chemotherapy and pharmacology* **71**, 647–56 (2013).
- Deng, Y. *et al.* Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. *Xenobiotica; the fate of foreign compounds in biological systems* **43**, 443–53 (2013).
- Denton, C. L. *et al.* Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. *Journal of clinical pharmacology* **53**, 955–61 (2013).
- Devriese, L. a *et al.* Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer chemotherapy and pharmacology* **70**, 823–32 (2012).
- Diéras, V. *et al.* Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. *European journal of cancer (Oxford, England : 1990)* **49**, 25–34 (2013).
- Dinney, C. P. N. *et al.* Phase I trial of intravesical recombinant adenovirus mediated interferon- α 2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. *The Journal of urology* **190**, 850–6 (2013).
- Doi, T. *et al.* Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. *British journal of cancer* **107**, 429–34 (2012).
- Doi, T. *et al.* Phase I first-in-human study of TAK-285 , a novel investigational dual HER2 / EGFR inhibitor , in cancer patients Patient characteristics. *British Journal of Cancer* **106**, 666–672 (2012).
- Doi, T. *et al.* Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. *International journal of clinical oncology* **18**, 87–95 (2013).
- Doi, T. *et al.* Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 227–35 (2013).
- Drappatz, J. *et al.* Phase I study of GRN1005 in recurrent malignant glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 1567–76 (2013).
- Dubbelman, A.-C. *et al.* Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 653–63 (2012).
- El-Khoueiry, A. *et al.* The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. *Cancer chemotherapy and pharmacology* **72**, 53–64 (2013).
- Ellithy, M. M. A., El Baghdady, N. S. E. D. M., El Wakeel, L. M., Abdeltawab, K. A. & Badary, O. A. An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma. *American journal of clinical oncology* **36**, 514–8 (2013).
- Falchook, G. S. *et al.* Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. *The lancet oncology* **13**, 782–9 (2012).
- Falchook, G. S. *et al.* Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. *Lancet* **379**, 1893–901 (2012).
- Falke, J. *et al.* Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. *The Journal of urology* **189**, 2077–82 (2013).
- Fasol, U. *et al.* Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 1030–6 (2012).
- Finger, P. T. & Chin, K. J. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. *Ophthalmic plastic and reconstructive surgery* **28**, 85–9 (2012).
- Flaherty, K. T. *et al.* Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 568–76 (2012).
- Friday, B. *et al.* A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. *Anticancer research* **32**, 1689–96 (2012).
- Fujisaka, Y. *et al.* First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. *Investigational new drugs* **31**, 108–14 (2013).
- Fujiwara, Y. *et al.* A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 991–8 (2013).
- Galsky, M. D. *et al.* Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 1037–44 (2012).
- Goldman, J. W. *et al.* A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. *BMC cancer* **13**, 152 (2013).

- Gomez, H. L. *et al.* Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. *Anti-cancer drugs* **23**, 335–41 (2012).
- Gordon, M. S. *et al.* A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 21–7 (2013).
- Gordon, M. S. *et al.* A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. *Investigational new drugs* **31**, 409–16 (2013).
- Gross, M. E., Leichman, L., Lowe, E. S., Swaisland, A. & Agus, D. B. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. *Cancer chemotherapy and pharmacology* **69**, 273–80 (2012).
- Grossman, S. *et al.* Phase I study of terameprocol in patients with recurrent high-grade glioma. *Neuro-oncology* **14**, 511–7 (2012).
- Guo, J. *et al.* Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. *BMC cancer* **13**, 136 (2013).
- Hammond-Thelin, L. *et al.* Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. *Investigational new drugs* **30**, 316–26 (2012).
- Hanna, N. *et al.* Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. *Cancer gene therapy* **19**, 374–81 (2012).
- Hayashi, H. *et al.* Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. *Cancer science* **104**, 98–104 (2013).
- Heath, E. I. *et al.* A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. *Investigational new drugs* **30**, 1566–74 (2012).
- Hemstreet, G. P. *et al.* Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. *Journal of immunotherapy (Hagerstown, Md. : 1997)* **36**, 57–65 (2013).
- Holen, K. *et al.* A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. *Investigational new drugs* **30**, 1088–95 (2012).
- Honda, K. *et al.* Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **72**, 577–84 (2013).
- Hong, D. S. *et al.* A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 4173–82 (2012).
- Hui, E. P. *et al.* Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. *Cancer research* **73**, 1676–88 (2013).
- Infante, J. R. *et al.* A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **69**, 165–72 (2012).
- Infante, J. R. *et al.* Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **30**, 1527–33 (2012).
- Infante, J. R. *et al.* Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. *The lancet oncology* **13**, 773–81 (2012).
- Isambert, N. *et al.* Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. *BMC cancer* **13**, 172 (2013).
- Ito, Y. *et al.* Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. *Japanese journal of clinical oncology* **42**, 278–86 (2012).
- Iwami, K. *et al.* Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor $\alpha 2$ chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. *Cytotherapy* **14**, 733–42 (2012).
- Jameson, G. S. *et al.* A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 268–78 (2013).
- Jia, N. *et al.* Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. *Anticancer research* **33**, 2797–800 (2013).
- Jimeno, A. *et al.* Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 2766–74 (2013).
- Kamigaki, T. *et al.* Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. *Anticancer research* **33**, 2971–6 (2013).
- Karbach, J. *et al.* Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 5449–59 (2012).
- Kelly, K. R. *et al.* Metabolism of patupilone in patients with advanced solid tumor malignancies. *Investigational new drugs* **31**, 605–15 (2013).
- Kesavabhotla, K., Schlaff, C. D., Mubita, L. & Kaplan, R. Phase I / II study of oral eriotinib for treatment of relapsed / refractory glioblastoma multiforme and anaplastic astrocytoma. *Journal of Experimental Therapeutics and Oncology* **10**, 71–81 (2012).
- Kim, K. H. *et al.* A phase I clinical trial of Ad5/3- $\Delta 24$, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. *Gynecologic oncology* **130**, 518–24 (2013).
- Kimura, T. *et al.* MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. *Cancer prevention research (Philadelphia, Pa.)* **6**, 18–26 (2013).
- Kitagawa, C. *et al.* Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. *Cancer chemotherapy and pharmacology* **69**, 1379–85 (2012).
- Kreisl, T. N. *et al.* A phase I/II trial of vandetanib for patients with recurrent malignant gliom. *Neuro-oncology* **14**, 1519–1526 (2012).

- Krop, I. *et al.* Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **30**, 2307–13 (2012).
- Kunz, P. L. *et al.* Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. *Investigational new drugs* **30**, 2364–70 (2012).
- Kurzrock, R. *et al.* Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. *Cancer* **118**, 6144–51 (2012).
- Lam, E. T. *et al.* Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **69**, 523–31 (2012).
- Lassen, U. *et al.* A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PIGF, in patients with advanced solid tumours. *British journal of cancer* **106**, 678–84 (2012).
- Leijen, S. *et al.* Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 4794–805 (2012).
- Li, J. *et al.* Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 57–63 (2012).
- Lorusso, P. M. *et al.* Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **30**, 4011–6 (2012).
- LoRusso, P. M. *et al.* Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 2954–63 (2012).
- Lu, C. *et al.* Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. *PLoS one* **7**, e34833 (2012).
- Lush, R. M. *et al.* A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. *Cancer chemotherapy and pharmacology* **70**, 567–74 (2012).
- Mamot, C. *et al.* Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. *The lancet oncology* **13**, 1234–41 (2012).
- Martinez-Garcia, M. *et al.* First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 4806–19 (2012).
- Massard, C. *et al.* Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. *Investigational new drugs* **30**, 2318–26 (2012).
- Massard, C. *et al.* Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. *Investigational new drugs* **31**, 623–30 (2013).
- Mita, M. M. *et al.* Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **24**, 1104–11 (2013).
- Morgan, R. A. *et al.* Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. *J Immunother* **36**, 133–151 (2013).
- Morita, S. *et al.* Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. *Investigational new drugs* **30**, 1950–7 (2012).
- Morris, D. G. *et al.* REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. *Investigational new drugs* **31**, 696–706 (2013).
- Morris, M. J. *et al.* A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 2714–9 (2012).
- Mross, K. *et al.* A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 2658–67 (2012).
- Mukohara, T., Nagai, S., Mukai, H., Namiki, M. & Minami, H. Eribulin mesylate in patients with refractory cancers: a Phase I study. *Investigational new drugs* **30**, 1926–33 (2012).
- Murakami, H. *et al.* Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/ gefitinib (LUX-Lung 4). *Cancer chemotherapy and pharmacology* **69**, 891–9 (2012).
- Murakami, H. *et al.* Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 407–14 (2012).
- Naing, A. *et al.* A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. *Investigational new drugs* **30**, 327–34 (2012).
- Nokihara, H. *et al.* A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. *Cancer chemotherapy and pharmacology* **70**, 559–65 (2012).
- O'Day, S. J. *et al.* Clinical and pharmacologic evaluation of two dose levels of intetumumab (CANTO 95) in patients with melanoma or angiosarcoma. *Investigational new drugs* **30**, 1074–81 (2012).
- O'Donnell, P. H. *et al.* A phase I study of continuous infusion cilengitide in patients with solid tumors. *Investigational new drugs* **30**, 604–10 (2012).
- Oehler, C. *et al.* Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. *Oncology* **83**, 1–9 (2012).
- Okamoto, I. *et al.* Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. *Cancer science* **103**, 2135–8 (2012).
- Okamoto, W. *et al.* A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **72**, 1063–71 (2013).

- Okusaka, T., Ueno, H., Ikeda, M., Takezako, Y. & Morizane, C. Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. *Cancer science* **103**, 1524–30 (2012).
- Ott, P. a *et al.* Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. *Investigational new drugs* **31**, 425–34 (2013).
- Pan, J. *et al.* Phase I study of nelfinavir in liposarcoma. *Cancer chemotherapy and pharmacology* **70**, 791–9 (2012).
- Pardo, B. *et al.* Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. *Medical oncology (Northwood, London, England)* **29**, 2240–50 (2012).
- Patnaik, A. *et al.* Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. *Cancer chemotherapy and pharmacology* **71**, 1499–506 (2013).
- Patterson, D. M. *et al.* Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 1415–25 (2012).
- Phuphanich, S. *et al.* Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. *Cancer immunology, immunotherapy : CII* **62**, 125–35 (2013).
- Pishvaian, M. J. *et al.* A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. *Cancer* **118**, 5403–13 (2012).
- Ramanathan, R. K. *et al.* A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. *Investigational new drugs* **30**, 1591–6 (2012).
- Rathkopf, D. E. *et al.* Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **31**, 3525–30 (2013).
- Reardon, D. a *et al.* Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. *Cancer chemotherapy and pharmacology* **69**, 849–60 (2012).
- Ribas, A. *et al.* Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. *Journal of translational medicine* **10**, 236 (2012).
- Rocha-Lima, C. M. *et al.* A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. *Cancer* **118**, 4262–70 (2012).
- Rong, Y. *et al.* A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. *Clinical and experimental medicine* **12**, 173–80 (2012).
- Rosen, L. S. *et al.* A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 4820–9 (2012).
- Rosen, L. S. *et al.* The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. *BMC cancer* **13**, 242 (2013).
- Saif, M. W. *et al.* Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. *Cancer chemotherapy and pharmacology* **71**, 1345–55 (2013).
- Salazar, R. *et al.* Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **72**, 75–83 (2013).
- Salazar, R. *et al.* A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 673–81 (2012).
- Sandhu, S. K. *et al.* A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. *Cancer chemotherapy and pharmacology* **71**, 1041–50 (2013).
- Sandhu, S. K. *et al.* The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *The lancet oncology* **14**, 882–92 (2013).
- Santoro, a *et al.* A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. *British journal of cancer* **108**, 21–4 (2013).
- Sawada, Y. *et al.* Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 3686–96 (2012).
- Schöffski, P. *et al.* A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. *European journal of cancer (Oxford, England : 1990)* **48**, 179–86 (2012).
- Schwartz, G. K. *et al.* Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. *Investigational new drugs* **31**, 370–80 (2013).
- Seki, Y. *et al.* Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **69**, 1099–105 (2012).
- Senzer, N. *et al.* Phase I Trial of “ bi-shRNAi furin / GMCSF DNA / Autologous Tumor Cell ” Vaccine (FANG) in Advanced Cancer. *Molecular Therapy* **20**, 679–686 (2009).
- Shapiro, G. I. *et al.* A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. *Investigational new drugs* **31**, 742–50 (2013).
- Slovin, S. F. *et al.* A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. *Vaccine* **31**, 943–9 (2013).
- Smith, C. *et al.* Effective Treatment of Metastatic Forms of Epstein-Barr Virus – Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy Effective Treatment of Metastatic Forms of Epstein-Barr Virus – Associated Nasopharyngeal Carcinoma wi. (2012). doi:10.1158/0008-5472.CAN-11-3399
- Soria, J.-C. *et al.* Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 463–71 (2012).
- Speranza, G. *et al.* Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors. *Cancer chemotherapy and pharmacology* **69**, 431–8 (2012).

- Spitaleri, G. *et al.* Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. *Journal of cancer research and clinical oncology* **139**, 447–55 (2013).
- Stebbing, J. *et al.* An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **23**, 1314–9 (2012).
- Stemmer, S. M. *et al.* CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. *The oncologist* **18**, 25–6 (2013).
- Stephenson, C. M., Levin, R. D., Spector, T. & Lis, C. G. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. *Cancer chemotherapy and pharmacology* **72**, 139–46 (2013).
- Strieth, S. *et al.* Phase I clinical study of vascular targeting fluorescent cationic liposomes in head and neck cancer. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery* **270**, 1481–7 (2013).
- Strumberg, D. *et al.* Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. *British journal of cancer* **106**, 1722–7 (2012).
- Tada, F. *et al.* Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. *International journal of oncology* **41**, 1601–9 (2012).
- Takahashi, T. & Boku, N. Phase I and pharmacokinetic study of dacotinib (PF-00299804), an oral irreversible , small molecule inhibitor of human epidermal growth factor receptor-1 , -2 , and -4 tyrosine kinases , in Japanese patients with advanced solid tumors. *Investigational new drugs* **30**, 2352–2363 (2012).
- Tevaarwerk, A. *et al.* Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. *Investigational new drugs* **30**, 1039–45 (2012).
- Tibes, R. *et al.* A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 463–71 (2013).
- Tolcher, A. W. *et al.* Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **30**, 2348–53 (2012).
- Topalian, S. L. *et al.* Safety, activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *The New England journal of medicine* **366**, 2443–2454 (2012).
- Trocóniz, I. F. *et al.* Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **70**, 239–50 (2012).
- Van Herpen, C. M. L. *et al.* Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. *Anti-cancer drugs* **24**, 204–11 (2013).
- Vilar, E. *et al.* A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. *Investigational new drugs* **30**, 299–305 (2012).
- Von Gruenigen, V. E. *et al.* Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. *Anti-cancer drugs* **23**, 724–30 (2012).
- Wang-Gillam, A. *et al.* A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors. *Investigational new drugs* **30**, 266–72 (2012).
- Wang-Gillam, A. *et al.* A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. *Investigational new drugs* **30**, 1958–61 (2012).
- Warso, M. a *et al.* A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. *British journal of cancer* **108**, 1061–70 (2013).
- Weekes, C. D. *et al.* Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 1232–43 (2013).
- Weiss, G. J. *et al.* Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. *Investigational new drugs* **30**, 2334–43 (2012).
- Whalen, G. F., Sullivan, M., Piperdi, B., Wasseff, W. & Galili, U. R. I. Cancer Immunotherapy by Intratumoral Injection of α -gal Glycolipids. *Anticancer research* **32**, 3861–3868 (2012).
- Wolin, E. M. *et al.* Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I stud. *Cancer chemotherapy and pharmacology* **72**, 387–95 (2013).
- Xiao, Z.-Y., Jia, J.-B., Chen, L., Zou, W. & Chen, X.-P. Phase I clinical trial of continuous infusion of tyrosinleutide in patients with advanced hepatocellular carcinoma. *Medical oncology (Northwood, London, England)* **29**, 1850–8 (2012).
- Yamamoto, N. *et al.* The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* **24**, 1653–9 (2013).
- Yamamoto, N. *et al.* A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. *Cancer science* **103**, 504–9 (2012).
- Yamamoto, N. *et al.* Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. *Cancer chemotherapy and pharmacology* **71**, 1645–55 (2013).
- Yang, S.-H., Lin, C.-C., Lin, Z.-Z., Tseng, Y.-L. & Hong, R.-L. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. *Investigational new drugs* **30**, 282–9 (2012).
- Yap, T. a *et al.* First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. *British journal of cancer* **106**, 1379–85 (2012).

- Yap, T. a *et al.* First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. *Clinical cancer research : an official journal of the American Association for Cancer Research* **19**, 909–19 (2013).
- Yarom, N. *et al.* Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. *Current clinical pharmacology* **8**, 81–8 (2013).
- Yau, T. *et al.* A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. *Investigational new drugs* **31**, 99–107 (2013).
- Yeo, W. *et al.* Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Res. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **30**, 3361–7 (2012).
- Yoshimura, K., Minami, T., Nozawa, M. & Uemura, H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. *British journal of cancer* **108**, 1260–6 (2013).
- Zhou, A. *et al.* Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. *Cancer chemotherapy and pharmacology* **72**, 1043–53 (2013).